Activated Probiotics Biome Her Probiotic

Ailments

• Vaginal dysbiosis
• Bacterial vaginosis
• Vulvovaginal
• Candidiasis (thrush)
• Urinary tract infections

Video

Instructions For Use

Can be taken Orally or as a Pessary, see the video TAB and Clinical Study TAB

Adults:

Orally: take 1 capsule daily (with or without food), or as directed by your healthcare practitioner.

As a Pessary:

Phase 1 = One capsule inserted into the vagina on alternate days for 10 consecutive nights

Phase 2 =  One capsule inserted into the vagina every week for the next 10 weeks

• dip capsule in warm water before inserting (best before bed), OR
• open capsule & mix with personal care cream before application, OR
• open capsule & pour powder on the inside layer of underwear before bed

Ingredients

*BLB = Billion Live Bacteria"No Refrigeration Required

No Added

NO ADDED GMOs, wheat, gluten, dairy, lactose, fructose, yeast, nuts, seeds, peanut, soy, egg, fish, shellfish, or animal derivatives.

No artificial colours, flavours, sweeteners, or preservatives.

Suitable for vegetarians and vegans.

Warnings and Cautions

If symptoms persist, talk to your healthcare practitioner.

Storage Conditions

Fridge Free

Clinical Study

Activated Probiotics Biome Her Pessary research for Thrush (LA02 & LF10 probiotic strains):

See Pubmed for study HERE

• 58 women diagnosed with recurrent vulvovaginal candidiasis (?4 culture-confirmed episodes in a 12-mo period)
• All patients were given 200mg of fluconazole orally for 3 alternate days during the first treatment week
• Probiotic pessary: 2 phases

• During the second 10-week prophylactic phase, 49 of 57 (86.0%) patients remained free of clinical recurrence
• 42 of 58 women enrolled in the study (72.4%) experienced no clinical recurrence throughout the 7-month observation phase

Technical Information

A HEALTHY VAGINAL MICROBIOTA

• Unlike the gut microbiota, a healthy vaginal microbiome (VMB) is characterised by low diversity of microorganisms and Lactobacilli dominance.
• Lactobacilli are necessary for the production of lactic acid to help maintain optimal vaginal pH (3.5-4.5) and deter the growth of pathogenic microorganisms.
• Particular species of Lactobacilli protect against vaginal infections by producing lactic acid and antimicrobial metabolites such as hydrogen peroxide, competing for nutrients and adhesion sites, and promoting a healthy vaginal mucosal barrier.
• Across different women, there are five recognised vaginal microbial community state types (CSTs) characterised by the abundance of specific Lactobacilli species, including Lactobacillus crispatus (CST-I), L. gasseri (CST-II), L. iners (CST-III) and L. jensenii (CST-V).
• The fourth subtype (CST-IV) is characterised by a greater diversity of non-Lactobacilli microorganisms, which may be healthy in some ethnic groups or represent a dysbiotic vaginal microbiome.
• Although individual variations occur, L. crispatus is widely regarded as the best marker for vaginal microbiome health largely due to its proficiency in producing lactic acid and hydrogen peroxide1.

VULVOVAGINAL INFECTIONS AND DYSBIOSIS

• The two most common causes of vaginitis, bacterial vaginosis (40-50%) and vulvovaginal candidiasis (20-25%) are vulvovaginal infections (VVIs) associated with disruptions to the vaginal microbiome and can be regarded as various types of vaginal dysbiosis.
• Bacterial vaginosis (BV) is caused by a relative deficiency of Lactobacilli microorganisms and lactic acid (with a vaginal pH >4.5), and an overgrowth of a diverse community of anaerobic bacteria, such as Gardnerella vaginalis.
• While treatment with antibiotics is effective for short-term relief, 25% of women will experience a recurrence within 4 weeks and up to 50% within 3 months1.
• It?s also estimated that 70% of women will experience long-term recurrence.
• Vulvovaginal candidiasis (VVC) is caused by an overgrowth of opportunistic Candida species, 90% of which are C. albicans4.
• Disturbances to the Lactobacilli balance of the VMB, such as from antibiotic use, reduces competition for space, acidity levels and production of antifungal substances and allows for Candida overgrowth.
• Unfortunately, of all women treated with standard oral antifungals such as fluconazole, recurrence occurs in up to 57% within 6 months and an estimated 9% of women experience recurrent VVC, with at least 4 episodes occurring within a 12 month period4,5,6.

THE VAGINAL MICROBIOTA AND URINARY TRACT INFECTIONS

• Urinary tract infections (UTIs) are also associated with vaginal colonisation of non-native pathogens such as E. coli, with the vagina acting as a reservoir for the translocation of pathogens to the urethra, bladder and kidneys.
• Not surprisingly, a vaginal microbiome with increased colonisation of E. coli, depleted hydrogen peroxide producing Lactobacilli and a composition resembling BV are all associated with increased rates of recurrent UTIs7.
• Despite treatment, approximately 20% of women experience recurrent UTIs, defined as two or more UTIs in six months or three or more UTIs in one year8.

PSYCHOSOCIAL AND PHYSIOLOGICAL IMPACTS

• Recurrent genitourinary infections are a growing public health issue with large social, psychological and physiological consequences for affected women.
• Left untreated or inadequately controlled, vaginal microbiome dysbiosis can severely impact the systemic health of a woman and the outcomes of any future pregnancy.
• For example, BV has been associated with increased risks of sexually-transmitted infections, such as HIV, HSV-2, gonorrhoeae, chlamydia and trichomoniasis, preterm birth, early pregnancy loss, low infant birth weight, increased neonatal morbidity, higher rates of postpartum endometritis and pelvic inflammatory disease1,2.
• Particularly in those with recurrent symptoms, many women experience anxiety, shame, and concerns about hygiene.

THE ROLE OF PROBIOTICS

• The need for new therapeutic strategies to address genitourinary tract infections is growing due to significant rates of recurrence following treatment and an increase in antimicrobial-resistant pathogens, largely as a result of indiscriminate use of antibiotics and antifungals9.
• Due to the underlying disruptions in Lactobacilli balance in many genitourinary tract infections, probiotic supplements containing Lactobacilli strains native to the vaginal environment can help to restore Lactobacilli dominance and promote resolution of these infections.
• For example, women with recurrent VVC who were administered a combination of Lactobacillus fermentum LF10 (DSM 19187) and Lactobacillus acidophilus LA02 (DSM 21717) for 10 weeks following a single dose of fluconazole demonstrated a 14.3% recurrence rate 7 months after cessation of treatment (Figure 1).
• This is significantly lower than the recurrence rate of up to 57% observed in other studies using long-term prophylactic oral fluconazole over a 6 month period5.

References

1. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob [Internet]. 2020 Dec 28;19(1):5.
2. Paladine HL, Desai UA. Vaginitis: Diagnosis and Treatment. Am Fam Physician. 2018;97(5):321?9.
3. Vicariotto F, Mogna L, Del Piano M. Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis: A pilot study. J Clin Gastroenterol. 2014;48(December):S106?12.
4. Rosati D, Bruno M, Jaeger M, ten Oever J, Netea MG. Recurrent Vulvovaginal Candidiasis: An Immunological Perspective. Microorganisms [Internet]. 2020 Jan 21;8(2):144.
5. Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study. J Clin Gastroenterol. 2014;48(December):S102?5.
6. Center for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines. https://www.cdc.gov/ std/tg2015/candidiasis.htm
7. Stapleton AE. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectr. 2016;4(6).
8. Nikpoor P, Dwyer PL. Recurrent urinary tract infections: Management in women. Med Today. 2020;21(9):14?9.
9. Superti F, De Seta F. Warding Off Recurrent Yeast and Bacterial Vaginal Infections: Lactoferrin and Lactobacilli. Microorganisms [Internet]. 2020 Jan 17;8(1):130.